Alnylam Pharmaceuticals Inc (ALNY) - Net Assets
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has net assets worth $789.18 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.97 Billion) and total liabilities ($4.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Alnylam Pharmaceuticals Inc (ALNY) cash conversion ratio to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $789.18 Million |
| % of Total Assets | 15.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | 34.17% |
| 10-Year Change | -14.24% |
| Growth Volatility | 250.12 |
Alnylam Pharmaceuticals Inc - Net Assets Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore Alnylam Pharmaceuticals Inc (ALNY) long-term investment share to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual net assets of Alnylam Pharmaceuticals Inc from 2002 to 2025. For live valuation and market cap data, see Alnylam Pharmaceuticals Inc (ALNY) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $789.18 Million | +1076.33% |
| 2024-12-31 | $67.09 Million | +130.41% |
| 2023-12-31 | $-220.64 Million | -39.45% |
| 2022-12-31 | $-158.22 Million | -126.90% |
| 2021-12-31 | $588.20 Million | -42.12% |
| 2020-12-31 | $1.02 Billion | -29.36% |
| 2019-12-31 | $1.44 Billion | +10.50% |
| 2018-12-31 | $1.30 Billion | -26.29% |
| 2017-12-31 | $1.77 Billion | +91.96% |
| 2016-12-31 | $920.22 Million | -27.24% |
| 2015-12-31 | $1.26 Billion | +35.08% |
| 2014-12-31 | $936.27 Million | +246.32% |
| 2013-12-31 | $270.35 Million | +101.67% |
| 2012-12-31 | $134.05 Million | +13.61% |
| 2011-12-31 | $118.00 Million | -25.43% |
| 2010-12-31 | $158.23 Million | -11.09% |
| 2009-12-31 | $177.97 Million | -11.95% |
| 2008-12-31 | $202.12 Million | +1.48% |
| 2007-12-31 | $199.17 Million | -1.00% |
| 2006-12-31 | $201.17 Million | +225.63% |
| 2005-12-31 | $61.78 Million | +33.89% |
| 2004-12-31 | $46.14 Million | +272.77% |
| 2003-12-31 | $-26.71 Million | -474.84% |
| 2002-12-31 | $-4.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alnylam Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 669803900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.32 Million | 0.17% |
| Other Comprehensive Income | $-20.10 Million | -2.55% |
| Other Components | $7.51 Billion | 951.69% |
| Total Equity | $789.18 Million | 100.00% |
Alnylam Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nokia Corp ADR
NYSE:NOK
|
$39.25 Billion |
|
Prudential plc
MX:PUKN
|
$39.25 Billion |
|
Garmin Ltd
F:GEY
|
$39.27 Billion |
|
Commerzbank AG
XETRA:CBK
|
$39.44 Billion |
|
Bloom Energy Corp
NYSE:BE
|
$39.20 Billion |
|
Consolidated Edison Inc
NYSE:ED
|
$39.18 Billion |
|
Danone SA
F:BSND
|
$39.05 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
$38.92 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alnylam Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 67,088,000 to 789,176,000, a change of 722,088,000 (1076.3%).
- Net income of 313,747,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 14,421,001.
- Other factors increased equity by 393,919,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $313.75 Million | +39.76% |
| Other Comprehensive Income | $14.42 Million | +1.83% |
| Other Changes | $393.92 Million | +49.92% |
| Total Change | $- | 1076.33% |
Book Value vs Market Value Analysis
This analysis compares Alnylam Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 50.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $-14.02 | $295.63 | x |
| 2003-12-31 | $-28.33 | $295.63 | x |
| 2004-12-31 | $3.88 | $295.63 | x |
| 2005-12-31 | $2.81 | $295.63 | x |
| 2006-12-31 | $6.31 | $295.63 | x |
| 2007-12-31 | $5.15 | $295.63 | x |
| 2008-12-31 | $4.92 | $295.63 | x |
| 2009-12-31 | $4.27 | $295.63 | x |
| 2010-12-31 | $3.76 | $295.63 | x |
| 2011-12-31 | $2.78 | $295.63 | x |
| 2012-12-31 | $2.67 | $295.63 | x |
| 2013-12-31 | $4.39 | $295.63 | x |
| 2014-12-31 | $12.60 | $295.63 | x |
| 2015-12-31 | $15.06 | $295.63 | x |
| 2016-12-31 | $10.75 | $295.63 | x |
| 2017-12-31 | $19.51 | $295.63 | x |
| 2018-12-31 | $12.94 | $295.63 | x |
| 2019-12-31 | $13.17 | $295.63 | x |
| 2020-12-31 | $8.84 | $295.63 | x |
| 2021-12-31 | $4.97 | $295.63 | x |
| 2022-12-31 | $-1.30 | $295.63 | x |
| 2023-12-31 | $-1.77 | $295.63 | x |
| 2024-12-31 | $0.53 | $295.63 | x |
| 2025-12-31 | $5.86 | $295.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alnylam Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 39.76%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.45%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 6.29x
- Recent ROE (39.76%) is above the historical average (-53.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.67 Million |
| 2003 | 0.00% | -14223.30% | 0.01x | 0.00x | $-22.36 Million |
| 2004 | -70.77% | -763.30% | 0.06x | 1.43x | $-37.27 Million |
| 2005 | -69.46% | -750.77% | 0.06x | 1.59x | $-49.09 Million |
| 2006 | -17.20% | -128.51% | 0.11x | 1.19x | $-54.73 Million |
| 2007 | -42.91% | -167.92% | 0.10x | 2.48x | $-105.38 Million |
| 2008 | -12.99% | -27.30% | 0.17x | 2.74x | $-46.46 Million |
| 2009 | -26.74% | -47.34% | 0.21x | 2.70x | $-65.39 Million |
| 2010 | -27.50% | -43.50% | 0.25x | 2.49x | $-59.34 Million |
| 2011 | -48.86% | -69.66% | 0.29x | 2.39x | $-69.45 Million |
| 2012 | -79.08% | -158.88% | 0.23x | 2.14x | $-119.42 Million |
| 2013 | -33.00% | -189.17% | 0.11x | 1.56x | $-116.26 Million |
| 2014 | -38.49% | -712.79% | 0.05x | 1.15x | $-454.02 Million |
| 2015 | -22.94% | -705.83% | 0.03x | 1.10x | $-416.54 Million |
| 2016 | -44.57% | -869.63% | 0.04x | 1.37x | $-502.13 Million |
| 2017 | -27.79% | -545.95% | 0.05x | 1.13x | $-667.52 Million |
| 2018 | -58.49% | -1016.58% | 0.05x | 1.21x | $-891.69 Million |
| 2019 | -61.59% | -403.24% | 0.09x | 1.66x | $-1.03 Billion |
| 2020 | -84.46% | -174.15% | 0.14x | 3.35x | $-959.91 Million |
| 2021 | -144.99% | -101.01% | 0.23x | 6.19x | $-911.64 Million |
| 2022 | 0.00% | -109.04% | 0.29x | 0.00x | $-1.12 Billion |
| 2023 | 0.00% | -24.08% | 0.48x | 0.00x | $-418.18 Million |
| 2024 | -414.62% | -12.37% | 0.53x | 63.20x | $-284.87 Million |
| 2025 | 39.76% | 8.45% | 0.75x | 6.29x | $234.83 Million |
Industry Comparison
This section compares Alnylam Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc (ALNY) | $789.18 Million | 0.00% | 5.29x | $39.21 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more